$1.21
▲ +0.8% Today
as of Sep 4, 16:51 ET
Last 30 days
Recent Press Releases & News
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
Overview
52-week range
$1.00
$3.06
10% of range
Avg surprise (last 3)
-213.6%
Avg reaction (last 2)
-5.6%
0% positive
Latest IV / EM
288%
EM ±44.9% · $1 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.21 | — | — | — | — | financials |
| Wed May 13, 2026 | Mar/2026 | $-0.20 | $-0.03 | -566.7% | +35.5% | -9.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.12 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.20 | $-0.18 | -11.1% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.31 | $-0.19 | -63.2% | — | -1.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.14 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.14 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.21 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.35 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.37 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.35 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $559,000 | $238,000 | — | — | $0 | $0 | — | — |
| Cost of revenue | $32,000 | $14,000 | — | — | $0 | $0 | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-26M | $-24M | — | $-12M | $-13M | $-21M | — | $-10M |
| Net income | $-29M | $-26M | — | $-12M | $-13M | $-21M | — | $-9M |
| EPS (diluted) | $-0.21 | $-0.20 | — | $-0.12 | $-0.20 | $-0.31 | — | $-0.14 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $170M | $71M | $73M | $47M | $42M | $45M | $25M | $13M |
| Inventory | $5M | $2M | $648,000 | — | — | — | — | — |
| Total current assets | $180M | $192M | $112M | $87M | $46M | $60M | $74M | $81M |
| Total assets | $182M | $194M | $114M | $88M | $47M | $62M | $75M | $83M |
| Long-term debt | $59M | $58M | $57M | $56M | $55M | $54M | $53M | $52M |
| Total liabilities | $163M | $158M | $72M | $67M | $65M | $68M | $62M | $59M |
| Total equity | $18M | $36M | $42M | $21M | $-18M | $-6M | $13M | $24M |